Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lyell Immunopharma
Biotech
Lyell signs deal for phase 1-stage colorectal cancer CAR-T
Lyell is handing over $40 million in cash and almost 2 million of its shares to secure a phase 1-stage CAR-T cell therapy for colorectal cancer.
James Waldron
Nov 10, 2025 9:45am
Sanofi vaccine vet vaults to GSK—Chutes & Ladders
Jun 13, 2025 8:30am
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Lyell loses 25% of staff, CMO to conserve cash post-GSK collab
Nov 8, 2023 7:41am
EMD Serono taps new COO—Chutes & Ladders
Jul 7, 2023 9:30am
GSK pays out £30M to Adaptimmune as cell therapy work ends
Apr 11, 2023 11:47am
